Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.
Alexa B KimballErrol P PrensThierry PasseronEmanual MaverakisIrina TurchinStefan BeeckLeonidas DrogarisZiqian GengTianyu ZhanIzabella MessinaFalk G BecharaPublished in: Dermatology and therapy (2023)
ClinicalTrials.gov identifier: NCT03926169.